Latham & Watkins advised Pionyr on the sale.Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of Pionyr…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
